Indegene

570.15
-4.70
(-0.82%)
ann
There are new updates from the company6 hours ago
Viewcross
right
Market Cap
13,681.01 Cr
EPS
15.19
PE Ratio
36.09
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
736.30
52 Week Low
470.10
PB Ratio
5.84
Debt to Equity
0.40
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
HOLD
Analysts have suggested that investors can hold this stock
Buy
Buy+25.00 %
+25.00 %
Hold
Hold+50.00 %
+50.00 %
Sell
Sell+25.00 %
+25.00 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
727.00
#1 29,264.44
61.48
#1 3,579.20
9.66
#1 510
17.58
55.64
570.15
#2 13,681.01
#2 36.09
#2 2,665.90
#3 12.77
#2 337
#6 11.03
53.38
126.32
2,754.71
-
32.80
#1 49.09
-105
6.46
54.30
972.20
2,160.50
35.92
322.30
0.22
41
112.87
49.57
87.31
205.54
-
769.70
-22.39
-59
17.26
57.73
8.67
128.26
-
67.20
-65.97
-120
#1 2,371.43
52.07
42.00
66.48
94.48
40.30
8.04
-1
120.00
49.00
16.00
26.30
#1 33.09
80.00
-3.26
2
-80.00
37.86
24.20
15.30
-
9.80
40.00
-9
-380.00
42.85
Growth Rate
Revenue Growth
12.77 %
Net Income Growth
26.53 %
Cash Flow Change
289.94 %
ROE
-5.80 %
ROCE
14.22 %
EBITDA Margin (Avg.)
13.59 %

Quarterly Financial Results

Quarterly Financials
Jun 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
540
645
636
647
687
699
699
708
758
Expenses
413
535
511
515
525
534
548
561
589
EBITDA
127
111
125
133
162
164
151
148
170
Operating Profit %
21 %
15 %
16 %
19 %
22 %
21 %
19 %
18 %
18 %
Depreciation
10
20
20
20
18
19
20
19
20
Interest
2
12
13
12
12
12
12
4
3
Profit Before Tax
115
79
93
101
132
134
120
124
146
Tax
29
30
24
26
34
39
32
32
37
Net Profit
86
49
68
75
99
95
88
92
110
EPS in ₹
3.88
2.20
3.09
3.38
4.45
4.27
3.79
3.84
4.59

Balance Sheet

Balance Sheet
2019
2020
2021
2022
2023
2024
Total Assets
329
600
596
1,354
2,204
2,546
Fixed Assets
104
119
86
138
664
646
Current Assets
185
418
459
1,130
1,449
1,791
Capital Work in Progress
0
0
0
0
0
0
Investments
0
13
0
120
614
797
Other Assets
225
468
510
1,096
926
1,103
Total Liabilities
329
600
596
1,354
2,204
2,546
Current Liabilities
158
247
199
440
489
611
Non Current Liabilities
18
369
64
149
651
506
Total Equity
152
-16
333
764
1,064
1,429
Reserve & Surplus
73
-105
324
764
1,020
1,385
Share Capital
79
0
0
0
44
44

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
Net Cash Flow
25
143
-41
373
-433
115
Investing Activities
-18
-16
-81
-158
-896
-327
Operating Activities
65
22
172
297
130
508
Financing Activities
-21
136
-132
234
333
-66

Share Holding

% Holding
Dec 2022
Mar 2024
Apr 2024
May 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
FIIs
0.00 %
3.56 %
0.00 %
0.00 %
3.79 %
4.82 %
5.03 %
DIIs
0.00 %
5.33 %
0.00 %
0.00 %
3.84 %
3.17 %
3.98 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
11.38 %
0.00 %
0.00 %
24.67 %
24.32 %
26.41 %
Others
100.00 %
79.73 %
100.00 %
100.00 %
67.70 %
67.69 %
64.58 %
No of Share Holders
44
4,43,785
82
82
2,03,599
1,51,440
1,53,789

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Shareholder Meeting / Postal Ballot-Scrutinizer"s Report6 hours ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20183 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 30, 2025
Closure of Trading WindowMar 27, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMar 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 26, 2025
Corrective Action On NSE LetterMar 26, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMar 25, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 19, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 18, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotMar 17, 2025
Intimation Of Outcome Of Resolution Passed By CirculationMar 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 10, 2025
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015 .Mar 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2025
Intimation Of Outcome Of Resolution Passed By Circulation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Intimation Of Resolution Proposed To Be Passed By Circulation.Feb 18, 2025
Intimation Regarding The Change Of Name Of Registrar And Transfer Agent (RTA) From Link Intime India Private Limited To MUFG Intime India Private LimitedFeb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 13, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 13, 2025
Integrated Filing (Financial)Feb 13, 2025
Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds For The Quarter Ended December 31 2024Feb 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 11, 2025
Integrated Filing (Financial)Feb 10, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 31, 2025
Intimation Of Opening Of Trading Window .Jan 31, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 31, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sJan 30, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 30, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 30, 2025
Results Financial Results- Dec 2024Jan 30, 2025
Board Meeting Outcome for Intimation Of Outcome Of Board MeetingJan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 24, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Quarter Ended December 31 2024.Jan 24, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJan 23, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 17, 2025

Technical Indicators

RSI(14)
Neutral
53.38
ATR(14)
Less Volatile
24.51
STOCH(9,6)
Neutral
74.57
STOCH RSI(14)
Overbought
85.57
MACD(12,26)
Bullish
2.72
ADX(14)
Weak Trend
19.47
UO(9)
Bearish
59.26
ROC(12)
Uptrend And Accelerating
0.58
WillR(14)
Neutral
-23.35

About Indegene

Indegene Limited is a global provider of digital-led commercialization services for the life sciences industry. The company offers solutions in analytics, technology, and commercial, medical, regulatory, and safety services to biopharmaceutical, emerging biotech, and medical devices companies. Indegene operates through four main segments: Enterprise Commercial Solutions, Omnichannel Activation, Enterprise Medical Solutions, and Others. These segments assist with digital marketing operations, last-mile promotion optimization, regulatory and medical operations consolidation, and clinical solutions and consultancy services. The company has made several acquisitions to expand its capabilities, including Encima Group, DT Associates, Cult Health, and Trilogy Writing & Consulting GmbH. In 2023, Indegene launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform. The company completed a public issue in May 2024, raising funds through a fresh issue and offer for sale.
Listing Date
13 May, 2024(0 Years, 37 days)
Chairperson Name